Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
U. Gatzemeier(Heidelberg University), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Terezie Janaskova(Asklepios Fachkliniken München-Gauting), Hanna Karnicka-Mlodkowski(Asklepios Fachkliniken München-Gauting), Rodryg Ramlau(Poznan University of Medical Sciences), Piotr Serwatowski(Heidelberg University), János Strausz(Országos Korányi Tbc és Pulmonológiai Intézet), A Płużańska(Fundación Instituto Valenciano de Oncología), Jaromı́r Roubec(Asklepios Fachkliniken München-Gauting), Janusz Milanowski(Asklepios Fachkliniken München-Gauting), Georgy M. Manikhas(City Clinical Oncology Center), Johan Vansteenkiste(Heidelberg University), E. Kaukel(Heidelberg University), Flavio De Rosa(Asklepios Fachkliniken München-Gauting), Aleksandra Szczęsna(Chinese University of Hong Kong), Miloš Pešek(Asklepios Fachkliniken München-Gauting)
Cited by 879
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k